NO20071175L - Sammensetning for langvarig medikamentfrigivning som viser et okende null-bestillende frigivningsmonster, fremgangsmate for fremstilling av en slik sammensetning - Google Patents

Sammensetning for langvarig medikamentfrigivning som viser et okende null-bestillende frigivningsmonster, fremgangsmate for fremstilling av en slik sammensetning

Info

Publication number
NO20071175L
NO20071175L NO20071175A NO20071175A NO20071175L NO 20071175 L NO20071175 L NO 20071175L NO 20071175 A NO20071175 A NO 20071175A NO 20071175 A NO20071175 A NO 20071175A NO 20071175 L NO20071175 L NO 20071175L
Authority
NO
Norway
Prior art keywords
composition
preparing
showing
prolonged drug
drug release
Prior art date
Application number
NO20071175A
Other languages
English (en)
Other versions
NO338672B1 (no
Inventor
Padmaja Shivanand
Gemma Casadevall
Ramkumar Subramanian
Brian L Barclay
Clark Allphin
Noymi V Yam
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NO20071175L publication Critical patent/NO20071175L/no
Publication of NO338672B1 publication Critical patent/NO338672B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Laminated Bodies (AREA)

Abstract

Det er fremlagt doseringsformer og metoder for vedvarende medikamentfrigivelse som innbefatter: en polymermatriks og mikroinnstøpt medikament, der forsinkelsessjiktet er hovedsakelig fri for ikke-mikroinnstøpt medikament; og et sekundærsjikt som innbefatter en polymermatriks og ikke-mikroinnstøpt medikamentmatriks; der det andre sjiktet befinner seg inntil forsinkelsessjiktet.
NO20071175A 2004-08-04 2007-03-01 Doseringsform for vedvarende frigivelse av medikament samt fremgangsmåte for fremstilling NO338672B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59912604P 2004-08-04 2004-08-04
PCT/US2005/027490 WO2006017537A1 (en) 2004-08-04 2005-08-02 Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition

Publications (2)

Publication Number Publication Date
NO20071175L true NO20071175L (no) 2007-05-03
NO338672B1 NO338672B1 (no) 2016-09-26

Family

ID=35229686

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071175A NO338672B1 (no) 2004-08-04 2007-03-01 Doseringsform for vedvarende frigivelse av medikament samt fremgangsmåte for fremstilling

Country Status (16)

Country Link
US (1) US20060034927A1 (no)
EP (1) EP1802286B1 (no)
JP (1) JP2008509144A (no)
KR (1) KR101340946B1 (no)
CN (1) CN101035519A (no)
AT (1) ATE401868T1 (no)
AU (1) AU2005271522B2 (no)
BR (1) BRPI0513089B8 (no)
CA (1) CA2575484A1 (no)
DE (1) DE602005008460D1 (no)
IL (1) IL181117A (no)
MX (1) MX2007001563A (no)
NO (1) NO338672B1 (no)
NZ (1) NZ552841A (no)
WO (1) WO2006017537A1 (no)
ZA (1) ZA200701878B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292700A1 (en) * 1997-04-21 2008-11-27 Biovail Laboratories Controlled release formulations using intelligent polymers
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008027600A2 (en) * 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Imatinib compositions
US8298576B2 (en) 2006-11-17 2012-10-30 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
MX2009003911A (es) * 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
US20090087487A1 (en) * 2007-08-21 2009-04-02 Michael Fox Paliperidone sustained release formulation
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
EP2081556A1 (en) * 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
BRPI0819231B8 (pt) * 2007-10-31 2021-05-25 Mcneil Ppc Inc processo para preparo de forma farmacêutica de desintegração rápida por moldagem a quente na presença de sal inorgânico hidratado
WO2009109993A1 (en) * 2008-02-04 2009-09-11 Torrent Pharmaceuticals Ltd. Extended release dosage form of paliperidone
WO2010009900A1 (en) * 2008-07-25 2010-01-28 Krka, D.D. Novo Mesto Paliperidone composition comprising solid matrix particles
EP2161019A1 (en) * 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
US20110177137A1 (en) * 2008-09-15 2011-07-21 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
WO2010089775A2 (en) * 2009-02-05 2010-08-12 Getz Pharma Research Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US8313768B2 (en) * 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
EP2485767A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
EP2547206B1 (en) 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
WO2012014052A2 (en) 2010-07-30 2012-02-02 Micro Labs Limited Novel coated extended release pharmaceutical compositions containing paliperidone
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
ES2456917T3 (es) 2011-05-31 2014-04-24 Laboratorios Farmacéuticos Rovi, S.A. Formulación de implante de paliperidona
PT2529756T (pt) 2011-05-31 2021-07-28 Farm Rovi Lab Sa Formulação de implante de risperidona e/ou paliperidona
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014167439A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of topiramate or salts thereof
CN103271889B (zh) * 2013-05-23 2015-10-28 沈阳药科大学 帕利哌酮新型递增释放渗透泵制剂及其制备方法
BR112016015944A8 (pt) 2014-01-10 2020-06-09 Johnson & Johnson Consumer Inc processo para produzir comprimido, que usa radiofrequência e partículas revestidas dissipadoras de energia
EP3448358B1 (de) * 2016-04-26 2021-09-08 LTS Lohmann Therapie-Systeme AG Filmförmige darreichungsform zur transmukosalen verabreichung von peptid-antidiabetika
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
GB201715109D0 (en) 2017-09-19 2017-11-01 Johnson Matthey Plc Release system and method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2236483B1 (no) * 1973-07-12 1976-11-12 Choay Sa
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
DE3508097A1 (de) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
US5011692A (en) * 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
DK0471036T4 (da) * 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
CA2264852C (en) * 1996-09-30 2005-11-01 Alza Corporation Use of methylphenidate or a pharmaceutically acceptable salt thereof
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ATE503472T1 (de) * 1996-11-15 2011-04-15 Ajinomoto Kk Nateglinide-tablettenzubereitungen
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
CA2395993A1 (en) * 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
GB0117618D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
NZ570198A (en) * 2002-07-29 2010-01-29 Alza Corp Methods and dosage forms for controlled delivery of paliperidone or risperidone

Also Published As

Publication number Publication date
NO338672B1 (no) 2016-09-26
BRPI0513089B1 (pt) 2019-10-29
AU2005271522A1 (en) 2006-02-16
JP2008509144A (ja) 2008-03-27
AU2005271522B2 (en) 2011-02-10
IL181117A (en) 2010-11-30
KR101340946B1 (ko) 2013-12-13
EP1802286B1 (en) 2008-07-23
DE602005008460D1 (de) 2008-09-04
BRPI0513089B8 (pt) 2021-05-25
WO2006017537A1 (en) 2006-02-16
EP1802286A1 (en) 2007-07-04
ZA200701878B (en) 2008-07-30
IL181117A0 (en) 2007-07-04
CN101035519A (zh) 2007-09-12
US20060034927A1 (en) 2006-02-16
NZ552841A (en) 2009-07-31
KR20070069136A (ko) 2007-07-02
MX2007001563A (es) 2008-03-05
ATE401868T1 (de) 2008-08-15
BRPI0513089A (pt) 2008-04-29
CA2575484A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
NO20071175L (no) Sammensetning for langvarig medikamentfrigivning som viser et okende null-bestillende frigivningsmonster, fremgangsmate for fremstilling av en slik sammensetning
AR052238A1 (es) Formulacion de tabletas estables
CY1122575T1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
DOP2009000137A (es) Composiciones farmaceuticas y sus metodos de uso
NO20100250L (no) Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav
NO20083462L (no) Nye tiofenderivater som S1P1/EDG1-reseptoragonister
NZ589437A (en) Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent
UY33075A (es) Derivados de ciclohexano y usos de los mismos
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
MX2009010289A (es) Composiciones para administracion nasal.
EP1755560A4 (en) PHARMACEUTICAL TABLETS WITH A RELATIVELY INACTIVE SEGMENT
NO20091299L (no) Substituerte sulfonamidderivater
UY28745A1 (es) Nuevos compuestos
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
TW200624126A (en) New modified release tablet formulations for proton pump inhibitors
BRPI0513909A (pt) comprimido farmacêutico de camada múltipla para a liberação controlada de ingredientes ativos com solubilidade altamente dependente do ph
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
NO20085414L (no) Farmasoytiske preparater for vedvarende frigivelse av fenylefrin
CY1118263T1 (el) Φλουρμπιπροφαινη ελεγχομενης εκλυσης και μυοχαλαρωτικοι συνδιασμοι
DK2101730T3 (da) Galenisk form til transmucosal indgivelse af paracetamol
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
ECSP088647A (es) Nueva sal de citrato de un derivado de indol y su uso farmacéutico
MX2023008573A (es) Modulador de via, composicion farmaceutica que tiene la misma, uso y metodo terapeutico que utiliza la misma.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees